Portola Pharmaceuticals is an American clinical stage biotechnology company that researches, develops, and commercializes drugs. The company focuses primarily on drugs used in the treatment of thrombosis and hematological malignancies. Founded in 2003 and headquartered in South San Francisco, California, Portola Pharmaceuticals is a member of the NASDAQ Biotechnology Index. In May 2020, Alexion Pharmaceuticals and Portola announced that they had entered into a definitive merger agreement for Alexion to acquire Portola.
Portola Pharmaceuticals has received investment from 1 venture capital firm.
Portola Pharmaceuticals is an American clinical stage biotechnology company that researches, develops, and commercializes drugs.
Portola Pharmaceuticals has received investment from Versant Ventures. These venture capital firms and investors provide both capital and strategic support.
Portola Pharmaceuticals was founded in 2003 and is headquartered in South San Francisco, California.
Portola Pharmaceuticals operates in the Biotech sector. Portola Pharmaceuticals is an American clinical stage biotechnology company that researches, develops, and commercializes drugs.
